S Ott1, T Wiegel2, S Laban3, T K Hoffmann3, C Petersen4, S Tribius5. 1. Kopf-Hals-Tumorzentrum des Comprehensive Cancer Center Ulm, Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, Ulm, 89081, Deutschland. saskia.ott@uniklinik-ulm.de. 2. Kopf-Hals-Tumorzentrum des Comprehensive Cancer Center Ulm, Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, Ulm, 89081, Deutschland. 3. Kopf-Hals-Tumorzentrum des Comprehensive Cancer Center Ulm, Klinik für Hals‑, Nasen‑, Ohrenheilkunde und Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Ulm, Deutschland. 4. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. 5. Hermann-Holthusen-Institut für Strahlentherapie, Asklepios Klinik St. Georg, Hamburg, Deutschland.
Abstract
BACKGROUND: Radiotherapy is an important treatment option in patients with advanced head and neck cancer. At the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), study results were presented that could further develop and modify existing therapy concepts in the future. MATERIALS AND METHODS: All ASCO abstracts and presentations concerning radiotherapy of head and neck cancer were screened and the most interesting abstracts were selected for further review. RESULTS: One major topic was the combination of radiation with immunotherapy. Presented trials included combination treatment of epidermal growth factor receptor (EGFR) antibodies and platin-based chemoradiotherapy, as well as programmed cell death protein 1 (PD-1) antibodies in combination with platin-based chemoradiotherapy or cetuximab radiotherapy. In one study, the impact of adjuvant (chemo)radiotherapy for overall survival of human papillomavirus (HPV)-associated head and neck cancer with low to intermediate risk was analyzed. Additionally, studies focusing on the prophylaxis or reduction of radiation-mediated oral mucositis were presented. CONCLUSION: The data presented do not justify a change of current treatment paradigms just yet. However, interesting developments can be expected in the coming years, particularly in the field of immunotherapy.
BACKGROUND: Radiotherapy is an important treatment option in patients with advanced head and neck cancer. At the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), study results were presented that could further develop and modify existing therapy concepts in the future. MATERIALS AND METHODS: All ASCO abstracts and presentations concerning radiotherapy of head and neck cancer were screened and the most interesting abstracts were selected for further review. RESULTS: One major topic was the combination of radiation with immunotherapy. Presented trials included combination treatment of epidermal growth factor receptor (EGFR) antibodies and platin-based chemoradiotherapy, as well as programmed cell death protein 1 (PD-1) antibodies in combination with platin-based chemoradiotherapy or cetuximab radiotherapy. In one study, the impact of adjuvant (chemo)radiotherapy for overall survival of human papillomavirus (HPV)-associated head and neck cancer with low to intermediate risk was analyzed. Additionally, studies focusing on the prophylaxis or reduction of radiation-mediated oral mucositis were presented. CONCLUSION: The data presented do not justify a change of current treatment paradigms just yet. However, interesting developments can be expected in the coming years, particularly in the field of immunotherapy.
Entities:
Keywords:
Antineoplastic combined chemotherapy protocols; Chemoradiotherapy; Head and neck neoplasms; Radiotherapy, adjuvant; Squamous cell carcinoma
Authors: K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Saumil J Gandhi; Andy J Minn; Robert H Vonderheide; E John Wherry; Stephen M Hahn; Amit Maity Journal: Cancer Lett Date: 2015-03-20 Impact factor: 8.679
Authors: Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl Journal: Strahlenther Onkol Date: 2018-03-02 Impact factor: 3.621
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang Journal: Lancet Oncol Date: 2009-11-10 Impact factor: 41.316
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Marij J P Welters; Wenbo Ma; Saskia J A M Santegoets; Renske Goedemans; Ilina Ehsan; Ekaterina S Jordanova; Vanessa J van Ham; Vincent van Unen; Frits Koning; Sylvia I van Egmond; Pornpimol Charoentong; Zlatko Trajanoski; Lilly-Ann van der Velden; Sjoerd H van der Burg Journal: Clin Cancer Res Date: 2017-10-10 Impact factor: 12.531
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245